Anmelden Kostenlos registrieren

Albireo Pharma Inc 1-Jahres-Ziel

Was ist das 1-Jahres-Ziel von Albireo Pharma Inc?

1-Jahres-Ziel von Albireo Pharma Inc ist $69 +55.31%

Was ist die Definition von 1-Jahres-Ziel?

1-Jahres-Ziel ist ein prognostizierter Aktienkurs pro Jahr.

One year target is an estimate of a stock price for a point in time equal to a year from the current date. The price level most often reflects the collective opinion of different analysts on where the stock will be trading a year from now. For an analyst to identify an individual estimate, they have to project what a company’s business will look like in a year, typically focusing on revenue and other significant factors. They also consider the willingness of investors to pay a certain price. While the average or median recommendation may be predictive and reflect the actual future value, the results are usually not extremely successful.

1-Jahres-Ziel von Unternehmen in Health Care Sektor auf NASDAQ im Vergleich zu Albireo Pharma Inc

Was macht Albireo Pharma Inc?

Albireo Pharma is a clinical-stage biopharmaceutical company focused on the development of novel bile acid modulators to treat rare pediatric and adult liver diseases, and other adult liver diseases and disorders. Albireo's lead product candidate, odevixibat, is being developed to treat rare pediatric cholestatic liver diseases with Phase 3 pivotal trials in PFIC, Alagille syndrome and biliary atresia. The Company completed IND-enabling studies for new preclinical candidate A3907 this year and plans to advance development in adult liver disease. Albireo was spun out from AstraZeneca in 2008 and is headquartered in Boston, Massachusetts, with its key operating subsidiary in Gothenburg, Sweden. The Boston Business Journal named Albireo one of the 2020 Best Places to Work in Massachusetts for the second consecutive year.

Unternehmen mit 1-jahres-ziel ähnlich Albireo Pharma Inc